Transgene Biotek (BOM:526139) Interest Expense: ₹-10.60 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:526139 Transgene Biotek Ltd BOM:526139
45 GF Score
Price ₹2.91
GF Value ₹6.63
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek Interest Expense?

Transgene Biotek BOM:526139 -3.64% 45 Interest Expense is ₹-10.60 Mil as of Mar. 2026. GuruFocus rates BOM:526139 with a GF Score™ of 45/100 and a GF Value™ of ₹6.63 (Possible Value Trap). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Transgene Biotek's interest expense for the three months ended in Mar. 2026 was ₹ -2.77 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-10.60 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Transgene Biotek's Operating Income for the three months ended in Mar. 2026 was ₹ -3.30 Mil. Transgene Biotek's Interest Expense for the three months ended in Mar. 2026 was ₹ -2.77 Mil. Transgene Biotek did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Transgene Biotek  (BOM:526139) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Transgene Biotek's Interest Expense for the three months ended in Mar. 2026 was ₹-2.77 Mil. Its Operating Income for the three months ended in Mar. 2026 was ₹-3.30 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was ₹68.01 Mil.

Transgene Biotek's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Transgene Biotek did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Transgene Biotek Interest Expense Historical Data

* Premium members only.

The historical data trend for Transgene Biotek's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Biotek Interest Expense Chart

Transgene Biotek Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.29 -6.24 -1.40 -2.43 -10.60

Transgene Biotek Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.91 -2.46 -2.64 -2.74 -2.77
BOM:526139
45GF Score
Transgene Biotek Ltd BOM:526139
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Biotek Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-10.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-10.60 Mil mean?
Transgene Biotek (BOM:526139) has a Interest Expense of ₹-10.60 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Transgene Biotek and its competitors.
Is Transgene Biotek's Interest Expense too high?
Transgene Biotek's current Interest Expense is ₹-10.60 Mil. Overall, Transgene Biotek has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Transgene Biotek's Interest Expense compare to VRTX and REGN?
Transgene Biotek's Interest Expense of ₹-10.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Transgene Biotek and its competitors. Transgene Biotek's current Interest Expense is ₹-10.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene Biotek stock overvalued right now?
Based on GuruFocus' analysis, Transgene Biotek (BOM:526139) is currently considered Possible Value Trap. The stock's GF Value™ is ₹6.63, compared to a current price of ₹2.91 — trading 56.1% below its estimated fair value. The current Interest Expense is ₹-10.60 Mil. Transgene Biotek's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Transgene Biotek (BOM:526139), the current Interest Expense is ₹-10.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹2.91 is trading 56.1% below its estimated GF Value™ of ₹6.63. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • Interest Expense: ₹-10.60 Mil
  • GF Value™: ₹6.63 vs. price of ₹2.91 (56.1% below fair value)
  • GF Score™: 45/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
45GF Score

Get the complete analysis for BOM:526139

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2.91
Price
₹6.63
GF Value